AstraZeneca And Ironwood Link Up To Bring Linaclotide To China
This article was originally published in PharmAsia News
Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.
You may also be interested in...
Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.
Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets
Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.